Povorcitinib not checked
Incyte Corporation · INCB054707 · INCB54707
FollowEvery change as it happens, and a Monday email
Trials
8 active
24 in total · 10 in the EU
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
- Tested for
- Hidradenitis Suppurativa (HS) (3 trials), NonSegmental Vitiligo (2 trials), Prurigo Nodularis (2 trials), Moderate to Severe Asthma
- Main trialPhase 3
- “This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.”In the company’s words, NCT06113445 on ClinicalTrials.gov
- Other names
- INCB054707 · INCB54707
Other drugs for Hidradenitis Suppurativa (HS)
- RuxolitinibIncyte · Novartis · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- LutikizumabAbbVie · Phase 3
- RemibrutinibNovartis · Phase 3
- BFB759Bluefin Biomedicine, Inc. · Phase 2/3
- SonelokimabMoonLake Immunotherapeutics AG · Phase 3
Coming up4
- 20 NovPhase 2 trial completes · ClinicalTrials.gov
- 26 DecPhase 3 trial completes · ClinicalTrials.gov
- 28 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 25 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 12 NovApproved in the EU · European Commission, Povofortay
- 13 NovCompletion date moved: 2026-10-19 to 2026-09-28 · ClinicalTrials.gov NCT06516965
Trials24
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 24 Feb 2026 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | |
| Phase 3Active, not recruiting | 17 Mar 2026 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | |
| Phase 3Active, not recruiting | 28 Sep 2026 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | |
| Phase 3Active, not recruiting | 19 Oct 2026 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | |
| Phase 3Active, not recruiting | 26 Dec 2026 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Recruiting | 28 Feb 2028 | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | |
| Phase 2Active, not recruiting | 20 Nov 2026 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | |
| Phase 2Recruiting | 25 Mar 2028 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 3Completed | 7 Jan 2025 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | |
| Phase 3Completed | 3 Feb 2025 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 2Completed | 22 Apr 2019 | A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | |
| Phase 2Completed | 13 Aug 2019 | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | |
| Phase 2Completed | 15 Dec 2021 | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | |
| Phase 2Completed | 24 May 2022 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo | |
| Phase 2Completed | 11 Aug 2023 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | |
| Phase 2Completed | 28 Feb 2025 | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | |
| Phase 1Completed | 25 Jan 2022 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707 | |
| Phase 1Completed | 30 Jun 2023 | A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | |
| Phase 1Completed | 7 Feb 2024 | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis | |
| Phase 1Completed | 7 Jun 2024 | A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females | |
| Phase 1Completed | 10 Sep 2024 | A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants | |
| Phase 1Completed | 18 Sep 2024 | A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants | |
| Phase 1Completed | 15 Jan 2025 | A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants | |
| Phase 1Completed | 8 Sep 2026 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026